Market Place
Sourcing Support
Sonnet BioTherapeutics Secures EU Patent For FHAB® Platform
28 Jan 2025 //
GLOBENEWSWIRE
Sonnet Bio To Present At LIVE with Webull Corporate Connect Webinar
22 Jan 2025 //
GLOBENEWSWIRE
Sonnet Bio Announces Release of the Next CEO Corner Segment
23 Dec 2024 //
GLOBENEWSWIRE
Sonnet BioTherapeutics Reports FY 2024 Results & Corporate Update
17 Dec 2024 //
GLOBENEWSWIRE
Sonnet Bio Announces $3.9M Offering & Private Placement
09 Dec 2024 //
GLOBENEWSWIRE
Sonnet Bio Releases Virtual Investor ‘”What this Means” Segment
12 Nov 2024 //
GLOBENEWSWIRE
Sonnet BioTherapeutics Prices $5M Underwritten Offering
06 Nov 2024 //
GLOBENEWSWIRE
Sonnet BioTherapeutics Announces Launch of CEO Corner Platform
30 Sep 2024 //
GLOBENEWSWIRE
Sonnet BioTherapeutics Announces Review of Strategic Alternatives
22 May 2024 //
ACCESSWIRE
Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business Update
14 Feb 2024 //
ACCESSWIRE
Sonnet Bio Announces Publication Demonstrating Suitability of SON-1210
21 Dec 2023 //
ACCESSWIRE
Sonnet BioTherapeutics Provides Fiscal Year 2023 Business Overview
31 Oct 2023 //
ACCESSWIRE
Sonnet BioTherapeutics Announces Results of Biodistribution Studies
20 Sep 2023 //
ACCESSWIRE
Sonnet BioTherapeutics Regains Nasdaq Minimum Bid Price Compliance
19 Sep 2023 //
ACCESSWIRE
Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010
18 Apr 2023 //
ACCESSWIRE
Sonnet Announces Webcast to Discuss Clinical Data from the SB101
17 Apr 2023 //
ACCESSWIRE
Sonnet Announces Completion of IND-Enabling Toxicology Studies with SON-1210
01 Feb 2023 //
ACCESSWIRE
J&J-partnered Sonnet halts work on bispecific, hunts for allies
16 Dec 2022 //
FIERCEBIOTECH
Sonnet BioTherapeutics Provides Fiscal Year 2022 Business and Financial Update
15 Dec 2022 //
ACCESSWIRE
Sonnet BioTherapeutics Announces Interim Data in Two Phase 1 Trials of SON-1010
02 Nov 2022 //
ACCESSWIRE
Sonnet Announces Webcast to Discuss Interim Data from the Company’s Phase 1
01 Nov 2022 //
ACCESSWIRE
Sonnet BioTherapeutics Announces an Agreement with Janssen
31 Oct 2022 //
ACCESSWIRE
Sonnet BioTherapeutics Regains Compliance with Nasdaq Minimum Bid Price
04 Oct 2022 //
ACCESSWIRE
Sonnet BioTherapeutics Appoints Ms. Lori McNeill to the Board of Directors
26 Sep 2022 //
ACCESSWIRE
Sonnet Bio Announces Progress in Two Phase 1 Dose-Escalation Trials of SON-1010
22 Sep 2022 //
PRESS RELEASE
Sonnet BioTherapeutics Provides Fiscal Year 2022 Third Quarter Update
15 Aug 2022 //
ACCESSWIRE
Sonnet BioTherapeutics Announces Trial of SON-1010 in Healthy Volunteers
21 Jul 2022 //
ACESSWIRE
Sonnet Bio Announces Positive Results from PC Combination Study of SON-1010
08 Jun 2022 //
ACCESSWIRE
Sonnet Bio Begins Dosing in PI Trial of SON-1010 for Advanced Solid Tumors
13 Apr 2022 //
ACCESSWIRE
Sonnet Bio Shows PC Data Supporting Bispecific Interleukin Candidates at AACR
08 Apr 2022 //
ACCESSWIRE
Sonnet Announces Successful Completion of the Discovery Phase for SON-1410
30 Aug 2021 //
BIOSPACE
Sonnet Provides Fiscal Year 2021 Third Quarter Business and Earnings Update
16 Aug 2021 //
PRESS RELEASE
Sonnet BioTherapeutics Completes Licensing Agreement with New Life Therapeutics
04 May 2021 //
BIOSPACE
Sonnet BioTherapeutics Announces Abstract Accepted for Presentation at AACR 2021
04 Feb 2021 //
BIOSPACE
Sonnet Completes Successful Repeat Dose Study of SON-1010
01 Feb 2021 //
NASDAQ
Sonnet Announces the Successful Completion Toxicology Study of SON-080
25 Jan 2021 //
BLOOMBERG
Sonnet BioTherapeutics Announces the Completion of a Successful
30 Nov 2020 //
APNEWS
Sonnet Announces At-The-Market Warrant Repricing and Exchange Resulting $10.5 M
04 Aug 2020 //
ACESSWIRE
Sonnet Signs Letter of Intent for Potential Licensing of Neuropathies Asset
04 Aug 2020 //
BIOSPACE
Sonnet Announces Positive Preclinical Results from an Initial Efficacy
20 Jul 2020 //
BIOSPACE
Sonnet BioTherapeutics Holdings Announces Merger Closing
01 Apr 2020 //
GLOBENEWSWIRE
